Ophthalmology Times

10/26/2026

The latest issue of Ophthalmology Times® is live! 👀

Read about the importance of treating EBMD before cataract surgery.
Learn about boosting premium IOL confidence through a mix-and-match approach,
the autonomous cataract practice, and closing the distance gap in GA treatment retention.

Check Out the Latest Issue of Ophthalmology Times 👇
https://hubs.li/Q04CgLzN0

10/23/2026

This marks the second phase 3 trial of Duravyu misses wet AMD noninferioroty end point; Eyepoint cuts 53% of staff to focus on DME.

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

Interim 48 month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier time points.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year end 2026.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovulessa for nAMD, DMO, RVO, and CNV ahead of an EC decision.

10/16/2026

The FDA has approved Enspryng for Thyroid Eye Disease, making it the first subcutaneous, at-home treatment option for TED and the first (IL)-6 receptor inhibitor approved for the indication.



AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

FDA advisors are set to review SYD-101, low dose atropine 0.01% for pediatric myopia, on October 30 after a complete response letter.

FDA accepts vamikibart BLA for UME as data show sustained gains at year 1; decision set for July 2027.

OT roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

10/15/2026

What a week for the Eye Care Network! 👁️ From New Orleans to Philadelphia, our Clinical Forums brought clinicians together for practical, case-based conversations that shape everyday practice.

A huge thank-you to our moderators:
Dr. Murtaza Adam
Dr. Roger Goldberg
Dr. Himani Goyal
Dr. Cathleen McCabe
Dr. Dilsher Dhoot
Dr. Travis Peck

And thank you to everyone who joined us. Swipe through for highlights!



Thank you, Dr. Dilsher Dhoot, for leading a standout Modern Retina Clinical Forum! A great group of retina specialists joined us for “Optimizing Anti-VEGF Therapy for RVO, AMD, and DME: Practical Strategies to Achieve Durable Disease Control,” trading real-world approaches to treatment intervals and long-term disease control.

Our dry eye Clinical Forum filled the room! Thank you, Dr. Cathleen McCabe Cathleen McCabe for leading such an engaging discussion, and to every clinician who shared their approach to diagnosing and treatment.

Stopped by our table? Thanks for grabbing the latest issues of Ophthalmology Times, Optometry Times, and Modern Retina!

Philadelphia, 10/13: case-based learning at its best! Attendees listened to real-world cases, with discussion around every scan. Thank you, Dr. Travis Peck, for an excellent session!

A special shout-out to the Wills Eye Hospital residents, fellows, and the local ophthalmologists who joined us on 10/13! It’s energizing to see the next generation of ophthalmologists in the room.

10/12/2026

That’s a wrap on ! 🎷
 
Our team spent the week in New Orleans capturing the conversations shaping eye care. A few highlights from the meeting:
 
🎥 Interviews with Quan D**g Nguyen, MD, and Stanford colleagues Dr. Jia-Horung Hung and Dr. Ngoc Than
 
🎙️ On-site Eichenbaum Acorns recordings with host David A. Eichenbaum, MD, FASRS, and guests Carl Danzig, MD, and Bindu Manne. Watch for those episodes, coming soon!
Produced by Sheryl Stevenson.
 
👏 A big thank you to our producers who covered the meeting from start to finish. Think you missed something? Head to the link in our bio for the latest AAO coverage!
 
See ya next year in Las Vegas, Nov. 12-15, 2027 🎰
 

10/09/2026

Made it to NOLA! 🎷

Swipe through for a look at the first day in New Orleans, from the flight in to the sessions halls to the essential beignet stop. ➡️

🔗 Click the link in our bio for the latest coverage from AAO.



Wheels up and headed south ✈️

Sunny skies on the Mississippi 🌞

Where all of ophthalmology meets

Packed rooms and plenty of surgical videos on the big screen

Fueled by cafe au lait and beignets ☕️

10/03/2026

Choosing a premium lens for cataract surgery can feel overwhelming. Ophthalmologist Eric Donnenfeld, MD, shares how sequencing the decision one eye at a time helps patients feel more confident and in control of their vision outcome.

Read more:

Sequencing IOL choice by eye can ease patient decision paralysis.

10/02/2026

Aldeyra Therapeutics is appealing the FDA's rejection of its dry eye disease drug reproxalap after the agency issued its third rejection letter earlier this year. The company says its clinical trial data support the drug's effectiveness and expects to meet with FDA officials later this year.

Read more:

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

10/01/2026

Nearsightedness in kids isn't just about needing glasses anymore — it can lead to permanent vision loss. Dr. Nimesh Patel explains why pediatric progressive myopia is becoming an epidemic and why he's asking the FDA to reconsider a promising treatment, SYD-101, for children at risk.

Read more:

Nimesh Patel, MD, urges the FDA to reconsider SYD-101 as pediatric myopia drives earlier retinal damage in US children.

10/01/2026

At Euretina 2026, Ritesh Narula, MBBS, MS, explains why AI’s greatest potential lies in imaging, where it can detect bio markers clinicians may miss and improve outcome prediction.
•
•
•
•